文献速递白血病

儿童急性淋巴细胞白血病鞘内甲氨蝶呤后血清药代动力学前瞻性评估

Prospective evaluation of serum methotrexate pharmacokinetics following intrathecal methotrexate in acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2026-10-23

该前瞻性研究对44例接受当代方案治疗的急性淋巴细胞白血病(ALL)患儿共124次鞘内甲氨蝶呤(IT-MTX)给药后血清MTX浓度进行监测,建立参考值并评估其与神经毒性的关联。结果显示IT-MTX后2-4小时平均血清浓度为0.62±0.56 μmol/L,24小时为0.057±0.039 μmol/L,48小时82%样本低于定量下限,表观终末半衰期为8.3小时。MTX相关神经毒性发生率为16%,与年龄≥10岁相关(p=0.02),但与血清MTX浓度无关。

要点

  • IT-MTX后2-4小时血清MTX平均浓度0.62±0.56 μmol/L,24小时降至0.057±0.039 μmol/L,48小时多数低于定量下限。
  • 表观终末半衰期为8.3小时,血清浓度在不同治疗阶段有轻度差异。
  • MTX相关神经毒性发生率为16%,与年龄≥10岁相关(p=0.02),与血清MTX浓度无关。

核心结论

  • 本研究建立了当代方案下标准IT-MTX给药后的参考血清MTX浓度,有助于临床解读疑似过量、用药错误或严重毒性时意外升高的血清MTX水平。

研究设计与样本

  • 前瞻性评估44例接受当代方案治疗的急性淋巴细胞白血病(ALL)患儿共124次鞘内甲氨蝶呤(IT-MTX)给药后的血清MTX药代动力学。
  • 在IT-MTX后2-4小时(TP1)、24小时(TP2)和48小时(TP3)测量血清MTX浓度,并评估其与MTX相关神经毒性的关联。

主要发现

  • IT-MTX后2-4小时平均血清MTX浓度为0.62±0.56 μmol/L,24小时为0.057±0.039 μmol/L。
  • 48小时时82%的样本低于定量下限,表观终末半衰期为8.3小时。
  • 血清MTX浓度在不同治疗阶段有轻度变化,巩固治疗期TP1浓度最高(p=0.042),延迟强化期TP2浓度最高(p=0.009)。
  • MTX相关神经毒性发生于44例患者中的7例(16%),与年龄≥10岁相关(p=0.02),但与血清MTX浓度无关。

关键数值与推荐

  • IT-MTX后2-4小时血清MTX平均浓度参考值为0.62±0.56 μmol/L。
  • IT-MTX后24小时血清MTX平均浓度参考值为0.057±0.039 μmol/L。
  • 表观终末半衰期为8.3小时;48小时时82%样本低于定量下限。
  • MTX相关神经毒性发生率16%(7/44),与年龄≥10岁相关(p=0.02)。

临床怎么用

  • 上述参考浓度可用于解读疑似IT-MTX过量、用药错误或严重毒性时意外升高的血清MTX水平。
  • 临床应关注年龄≥10岁患儿的MTX相关神经毒性风险,血清MTX浓度与神经毒性无关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum methotrexate (MTX) monitoring is standard following high-dose intravenous MTX but lacks established reference values after intrathecal (IT) administration, limiting interpretation during suspected IT-MTX toxicity or overdose. We prospectively evaluated serum MTX pharmacokinetics following 124 IT-MTX doses administered to 44 children with acute lymphoblastic leukaemia (ALL) treated on contemporary protocols to establish reference serum concentrations and assess association with MTX-related neurotoxicity. Serum MTX concentrations were measured at 2-4 h (TP1), 24 h (TP2) and 48 h (TP3) after IT-MTX. Mean concentrations were 0.62 ± 0.56 μmol/L at TP1, 0.057 ± 0.039 μmol/L at TP2; by TP3, 82% of samples were below the lower limit of quantification. The apparent terminal half-life was 8.3 h. Serum concentrations varied modestly across treatment phases, with the highest TP1 concentrations during consolidation (p = 0.042) and the highest TP2 concentrations during delayed intensification (DI) (p = 0.009). MTX-related neurotoxicity occurred in 7 of 44 patients (16%) and was associated with age ≥10 years (p = 0.02), but not with serum MTX concentrations. These findings establish contemporary reference serum MTX concentrations following standard IT-MTX administration that may assist clinicians in interpreting unexpectedly elevated serum MTX levels during suspected overdose, medication error or severe toxicity.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jastaniah W, Iraqi A, Kamel SA, et al. Prospective evaluation of serum methotrexate pharmacokinetics following intrathecal methotrexate in acute lymphoblastic leukaemia. Br J Haematol. 2026. PMID: 42919823. doi:10.1111/bjh.70904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。